Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk.
Overview
- Phase
- Phase 3
- Intervention
- triptorelin
- Conditions
- Prostate Cancer
- Sponsor
- UNICANCER
- Enrollment
- 424
- Locations
- 17
- Primary Endpoint
- Event-free survival
- Status
- Completed
- Last Updated
- 11 months ago
Overview
Brief Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether giving triptorelin and radiation therapy soon after surgery or later after surgery is more effective in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying giving triptorelin and radiation therapy soon after surgery to see how well it works compared with giving them later after surgery in treating patients who have undergone surgery for intermediate-risk stage III or stage IV prostate cancer.
Detailed Description
OBJECTIVES: Primary * Compare the efficacy, in terms of event-free survival at 5 years, of immediate radio-hormonal therapy immediately after prostatectomy for tumor pT2, R1, pN0, or pNx versus radio-hormonal therapy at biochemical relapse. Secondary * Compare the overall survival of patients treated with these regimens. * Compare the metastasis-free survival of these patients. * Compare the acute and late toxicities of these regimens in these patients. * Compare the quality of life of patients treated with these regimens. * Compare the functional dependence of patients over 75 years old. OUTLINE: Patients are randomized to 1 of 2 treatment arms. * Arm I (delayed treatment): Patients receive triptorelin intramuscularly on day 1 and then 3 months later. Patients also undergo conformal radiotherapy daily, 5 days a week, for 7 weeks. Treatment begins at biochemical relapse (PSA is more than 0.2 ng/mL) and before PSA is more than 2 ng/mL. * Arm II (immediate treatment): Patients receive treatment as in arm I, but treatment begins within 6 months after surgery. After completion of study treatment, patients are followed for up to 5 years.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
A Relapse
Radiotherapy and Hormonotherapy only if relapse
Intervention: triptorelin
A Relapse
Radiotherapy and Hormonotherapy only if relapse
Intervention: adjuvant therapy
A Relapse
Radiotherapy and Hormonotherapy only if relapse
Intervention: 3-dimensional conformal radiation therapy
B Immediate treatment
Radiotherapy and Hormonotherapy at randomization
Intervention: triptorelin
B Immediate treatment
Radiotherapy and Hormonotherapy at randomization
Intervention: adjuvant therapy
B Immediate treatment
Radiotherapy and Hormonotherapy at randomization
Intervention: 3-dimensional conformal radiation therapy
Outcomes
Primary Outcomes
Event-free survival
Time Frame: From randomization to disease progression or death, up to 5 years
The event-free survival is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse (clinical progression, biochemical progression, death)
Secondary Outcomes
- Acute or chronic toxicity(Throughout study completion, up to 10 years)
- Quality of life questionnaire - Core 30 (QLQ-C30)(At baseline, 2 years, and 5 years)
- Overall survival(From randomization to death from any cause, up to 10 years)
- Metastases-free survival(From randomization to metastases onset, up to 10 years)
- Quality of Life Questionnaire - Prostate Cancer Module (QLQ-PR25)(At baseline, 2 years, and 5 years)
- Functional dependence in patients over 75 years old(At baseline, 2 years, and 5 years)